Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.
Rivermark Medical has raised $20.0M in total funding. The most recent round was Series D. The last funding was announced in May 2026.
Rivermark Medical's investors include Andera Partners, Clarevia Ventures, TIME BioVentures, American Century Investments, Cadence Healthcare Ventures.
Rivermark Medical is headquartered in Milwaukee, United States.
Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.
Rivermark Medical is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rivermark Medical — Funding & Investors." VCBacked, May 13, 2026, https://www.vcbacked.co/company/rivermark-medical. Accessed July 31, 2026.
VCBacked. (2026). Rivermark Medical — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/rivermark-medical
{{cite web |title=Rivermark Medical — Funding & Investors |url=https://www.vcbacked.co/company/rivermark-medical |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated